The Importance of Quality Assurance in Radiation Oncology Clinical Trials

IF 2.6 3区 医学 Q3 ONCOLOGY Seminars in Radiation Oncology Pub Date : 2023-10-01 DOI:10.1016/j.semradonc.2023.06.005
Thomas J. FitzGerald , Maryann Bishop-Jodoin , Fran Laurie , Matthew Iandoli , Koren Smith , Kenneth Ulin , Linda Ding , Janaki Moni , M. Giulia Cicchetti , Michael Knopp , Stephen Kry , Ying Xiao , Mark Rosen , Fred Prior , Joel Saltz , Jeff Michalski
{"title":"The Importance of Quality Assurance in Radiation Oncology Clinical Trials","authors":"Thomas J. FitzGerald ,&nbsp;Maryann Bishop-Jodoin ,&nbsp;Fran Laurie ,&nbsp;Matthew Iandoli ,&nbsp;Koren Smith ,&nbsp;Kenneth Ulin ,&nbsp;Linda Ding ,&nbsp;Janaki Moni ,&nbsp;M. Giulia Cicchetti ,&nbsp;Michael Knopp ,&nbsp;Stephen Kry ,&nbsp;Ying Xiao ,&nbsp;Mark Rosen ,&nbsp;Fred Prior ,&nbsp;Joel Saltz ,&nbsp;Jeff Michalski","doi":"10.1016/j.semradonc.2023.06.005","DOIUrl":null,"url":null,"abstract":"<div><p>Clinical trials have been the center of progress in modern medicine. In oncology, we are fortunate to have a structure in place through the National Clinical Trials Network (NCTN). The NCTN provides the infrastructure and a forum for scientific discussion to develop clinical concepts for trial design. The NCTN also provides a network group structure to administer trials for successful trial management and outcome analyses. There are many important aspects to trial design and conduct. Modern trials need to ensure appropriate trial conduct and secure data management processes. Of equal importance is the quality assurance of a clinical trial. If progress is to be made in oncology clinical medicine, investigators and patient care providers of service need to feel secure that trial data is complete, accurate, and well-controlled in order to be confident in trial analysis and move trial outcome results into daily practice. As our technology has matured, so has our need to apply technology in a uniform manner for appropriate interpretation of trial outcomes. In this article, we review the importance of quality assurance in clinical trials involving radiation therapy. We will include important aspects of institution and investigator credentialing for participation as well as ongoing processes to ensure that each trial is being managed in a compliant manner. We will provide examples of the importance of complete datasets to ensure study interpretation. We will describe how successful strategies for quality assurance in the past will support new initiatives moving forward.</p></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"33 4","pages":"Pages 395-406"},"PeriodicalIF":2.6000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053429623000425","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Clinical trials have been the center of progress in modern medicine. In oncology, we are fortunate to have a structure in place through the National Clinical Trials Network (NCTN). The NCTN provides the infrastructure and a forum for scientific discussion to develop clinical concepts for trial design. The NCTN also provides a network group structure to administer trials for successful trial management and outcome analyses. There are many important aspects to trial design and conduct. Modern trials need to ensure appropriate trial conduct and secure data management processes. Of equal importance is the quality assurance of a clinical trial. If progress is to be made in oncology clinical medicine, investigators and patient care providers of service need to feel secure that trial data is complete, accurate, and well-controlled in order to be confident in trial analysis and move trial outcome results into daily practice. As our technology has matured, so has our need to apply technology in a uniform manner for appropriate interpretation of trial outcomes. In this article, we review the importance of quality assurance in clinical trials involving radiation therapy. We will include important aspects of institution and investigator credentialing for participation as well as ongoing processes to ensure that each trial is being managed in a compliant manner. We will provide examples of the importance of complete datasets to ensure study interpretation. We will describe how successful strategies for quality assurance in the past will support new initiatives moving forward.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
放射肿瘤学临床试验中质量保证的重要性。
临床试验一直是现代医学进步的中心。在肿瘤学领域,我们很幸运通过国家临床试验网络(NCTN)建立了一个结构。NCTN为开发试验设计的临床概念提供了科学讨论的基础设施和论坛。NCTN还提供了一个网络小组结构来管理试验,以成功进行试验管理和结果分析。试验设计和实施有许多重要方面。现代审判需要确保适当的审判行为和安全的数据管理程序。同样重要的是临床试验的质量保证。如果要在肿瘤学临床医学方面取得进展,研究人员和患者护理服务提供者需要确保试验数据完整、准确和控制良好,以便对试验分析充满信心,并将试验结果纳入日常实践。随着我们的技术的成熟,我们需要以统一的方式应用技术来适当解释试验结果。在这篇文章中,我们回顾了质量保证在放射治疗临床试验中的重要性。我们将包括机构和研究人员参与资格认证的重要方面,以及正在进行的流程,以确保每项试验都以合规的方式进行管理。我们将提供完整数据集重要性的示例,以确保研究解释。我们将介绍过去成功的质量保证战略将如何支持新的举措。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.80
自引率
0.00%
发文量
48
审稿时长
>12 weeks
期刊介绍: Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.
期刊最新文献
Radiation as an Immune Modulator: Where We Are With Modern Total Body Irradiation. Radiation for Multiple Myeloma in the Era of Novel Agents: Indications, Safety, and Dose Selection. Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin Lymphoma. Translating Between Radiation Dose and Late Toxicity for Lymphoma Survivors: Implications on Toxicity Counseling and Survivorship. Advanced Stage Hodgkin and Diffuse Large B-Cell Lymphomas: Is There Still a Role for Consolidation Radiotherapy in the PET Era?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1